ML133 HCl: Selective Kir2.1 Potassium Channel Inhibitor for Cardiovascular Research

Executive Summary: ML133 HCl is a selective potassium channel inhibitor, demonstrating potent inhibition of Kir2.1 channels with an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5 (APExBIO, product page). It exhibits minimal or no inhibitory activity against Kir1.1, Kir4.1, and Kir7.1, ensuring high experimental specificity. ML133 HCl has been validated in research models for its capacity to modulate pulmonary artery smooth muscle cell proliferation and migration, directly impacting cardiovascular disease modeling (Cao et al., DOI:10.3892/ijmm.2022.5175). The compound is insoluble in water but dissolves readily in DMSO and ethanol, with optimal storage at -20°C. Its documented experimental effects support translational research into pulmonary hypertension and vascular remodeling.

Biological Rationale

Inwardly rectifying potassium channels (Kir) are essential for cellular potassium ion transport and maintaining membrane potential. Kir2.1, encoded by the KCNJ2 gene, is a major subtype implicated in regulating vascular smooth muscle cell excitability and homeostasis (Cao et al. 2022). Dysregulation of Kir2.1 is associated with pathological vascular remodeling, particularly in pulmonary hypertension, where abnormal pulmonary artery smooth muscle cell (PASMC) proliferation and migration are central features. By specifically inhibiting Kir2.1, ML133 HCl provides a tool to dissect the contribution of this channel to cardiovascular disease models. The compound’s selectivity ensures that observed phenotypes are due to Kir2.1 blockade rather than off-target potassium channel effects (Advanced Insights in Kir2.1 Channel Inhibition), clarifying mechanistic pathways involved in vascular remodeling. This article extends prior reviews by providing a structured, evidence-backed integration of ML133 HCl's selectivity, application conditions, and experimental benchmarks.

Mechanism of Action of ML133 HCl

ML133 HCl is the hydrochloride salt of 1-(4-methoxyphenyl)-N-(naphthalen-1-ylmethyl)methanamine, with a molecular weight of 313.82 and formula C₁₉H₁₉NO·HCl (APExBIO). It functions as a selective, potent inhibitor of the Kir2.1 channel. At pH 7.4, its IC₅₀ is 1.8 μM; at pH 8.5, potency increases to 290 nM. ML133 HCl does not inhibit Kir1.1 and has only weak activity against Kir4.1 and Kir7.1, making it highly specific for Kir2.1. The compound binds to the Kir2.1 channel pore, thereby blocking potassium ion transport and altering membrane potential in target cells (Cao et al. 2022). This inhibition modulates downstream signaling pathways, notably suppressing TGF-β1/SMAD2/3 activation and reducing expression of proliferation markers such as OPN and PCNA in PASMCs. The net effect is reduced cell proliferation and migration, which are critical in models of pulmonary hypertension and vascular remodeling.

Evidence & Benchmarks

• ML133 HCl inhibits Kir2.1 potassium channels with an IC₅₀ of 1.8 μM at pH 7.4 and 290 nM at pH 8.5 (APExBIO).
• No inhibitory effect was observed on Kir1.1 channels, and only weak inhibition on Kir4.1 and Kir7.1 channels, confirming high selectivity (APExBIO).
• ML133 HCl pre-treatment (24 h) of human PASMCs reversed PDGF-BB-induced cell proliferation and migration, as demonstrated by scratch and Transwell assays (Cao et al. 2022).
• ML133 HCl inhibited PDGF-BB-upregulated OPN and PCNA expression and suppressed the TGF-β1/SMAD2/3 pathway in vitro (Cao et al. 2022).
• The compound is stable as a solid at -20°C but shows limited stability in solution, particularly in aqueous buffers (APExBIO).

This data supports ML133 HCl’s utility as a benchmark tool in selective Kir2.1 potassium channel inhibition and cardiovascular ion channel research. For deeper mechanistic exploration of Kir2.1 blockade, see this review, which this article updates by adding explicit evidence and new workflow benchmarks.

Applications, Limits & Misconceptions

ML133 HCl is used to investigate the role of Kir2.1 in pulmonary artery smooth muscle cell proliferation, migration, and vascular remodeling under controlled in vitro and in vivo conditions. It is integral to cardiovascular disease modeling, especially pulmonary hypertension, by allowing targeted modulation of potassium ion transport and downstream signaling pathways (Cao et al. 2022). Its high selectivity for Kir2.1 channels enables researchers to attribute observed phenotypes to specific channel blockade, rather than off-target effects.

Common Pitfalls or Misconceptions

• ML133 HCl is not a pan-potassium channel blocker; it is selective for Kir2.1 and does not meaningfully inhibit Kir1.1, Kir4.1, or Kir7.1 (APExBIO).
• The compound is insoluble in water; improper preparation may lead to precipitation and unreliable dosing.
• ML133 HCl is intended for research use only and not for clinical or therapeutic applications.
• Dissolved ML133 HCl is only stable short-term; long-term storage in solution leads to degradation (APExBIO).
• Inhibition of Kir2.1 does not address all mechanisms of vascular remodeling; parallel pathways may confound results if not controlled.

Workflow Integration & Parameters

ML133 HCl is supplied as a solid by APExBIO and should be stored at -20°C in a desiccated environment for maximal stability. It is insoluble in water but dissolves in DMSO (≥15.7 mg/mL) and ethanol (≥2.52 mg/mL) with gentle warming and sonication (APExBIO). For experimental use, researchers typically pre-treat PASMCs for 24 hours at concentrations determined by IC₅₀ and assay sensitivity. Short-term stock solutions should be prepared fresh, and aliquots discarded after single use to avoid compound degradation. When integrating ML133 HCl into vascular modeling protocols, ensure that solvent controls are included to account for DMSO or ethanol vehicle effects. For a systems-level view of Kir2.1 inhibition in cardiovascular research, see this article, which this dossier clarifies with updated product specifications and application boundaries.

Conclusion & Outlook

ML133 HCl is a validated, selective Kir2.1 potassium channel inhibitor that empowers precise dissection of potassium ion channel function in cardiovascular and vascular smooth muscle cell research. Its robust selectivity profile and reproducible experimental benchmarks position it as a reference compound for pulmonary artery smooth muscle cell proliferation and migration studies. With clear guidelines for preparation, storage, and use, ML133 HCl (APExBIO B2199) remains an indispensable tool in cardiovascular disease modeling and translational ion channel research (ML133 HCl product page). For comprehensive technical and mechanistic perspectives, consult the related article on cardiovascular ion channel research, which this review extends by integrating new evidence and mitigation of common laboratory pitfalls.